Targeted Therapy for Multiple Myeloma
Research type
Research Study
Full title
Targeted Nanotherapy for Multiple Myeloma
IRAS ID
335312
Contact name
Zahraa Al-Ahmady
Contact email
Sponsor organisation
Nottingham Trent University
Duration of Study in the UK
2 years, 2 months, 1 days
Research summary
In this project, we aim to design a novel lipid-based nanoparticle therapy that specifically targets the myeloma cells with little or no collateral damage and delivers a payload of novel therapies to myeloma cells. There is a huge potential in this project to create a modern line of therapy that can overcome many of the shortfalls within other available treatments. To undertake this project, we have a multidisciplinary team with expertise and a track record in the methods required. Dr Al-Ahmady will lead the project and design the targeted nanoparticle vectors and test those in vitro and in vivo, in collaboration with Dr Firas Al-Kaisi who will facilitate testing on primary samples.
REC name
Yorkshire & The Humber - South Yorkshire Research Ethics Committee
REC reference
24/YH/0066
Date of REC Opinion
11 Mar 2024
REC opinion
Favourable Opinion